Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Reuters

2025/11/10

Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Day One Biopharmaceuticals Inc. has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582690873"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582690873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582690873?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582690873","market":"us","top_or_hot":-1,"title":"Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals Inc.</a> has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting &amp; Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDay One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 20:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals Inc.</a> has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting &amp; Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9Sxsb:1","article_id":"2582690873","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582690873","pubTimestamp":1762776121,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Day One Biopharmaceuticals Inc. has announced that new data on OJEMDA  will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology , taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma  with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","DAWN":"Day One Biopharmaceuticals Inc.","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Day One Biopharmaceuticals报告OJEMDA在儿童低级别神经胶质瘤试验中的持久反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":0.9,"NDAQ":0.9},"content_text":"Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    \n\nDay One Biopharmaceuticals Inc. has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}